Table 1 Clinicopathological data for discovery and validation cohorts
Characteristics | Discovery TMA N = 145 (%) | Validation TMA N = 163 (%) |
|---|---|---|
Age | ||
 < 60 | 42 (29%) | 47 (29%) |
 = > 60 | 103 (71%) | 115 (71%) |
 Unknown | 0 (0%) | 1 (< 1%) |
Sex | ||
 Male | 115 (79%) | 117 (72%) |
 Female | 30 (21%) | 46 (28%) |
Tumour site | ||
 Esophagus | 8 (6%) | 71 (44%) |
 Stomach | 0 (0%) | 92 (56%) |
 GOJ, Siewert 1 | 81 (56%) | 0 (0%) |
 GOJ, Siewert 2 | 44 (30%) | 0 (0%) |
 GOJ, Siewert 3 | 12 (8%) | 0 (0%) |
T Stage | ||
 pT0/1 | 3 (2%) | 24 (15%) |
 pT2 | 11 (8%) | 55 (34%) |
 pT3 | 117 (81%) | 81 (49%) |
 pT4 | 2 (1%) | 3 (2%) |
 Unknown | 12 (8%) | 0 (0%) |
N Stage | ||
 N0 | 33 (23%) | 72 (44%) |
 N1 | 85 (59%) | 74 (45%) |
 N2/3 | 3 (2%) | 17 (11%) |
 Unknown | 24 (16%) | 0 (0%) |
Lymph node | ||
 Positive | 97 (67%) | 91 (56%) |
 Negative | 48 (33%) | 72 (44%) |
Mandard TRG | ||
 1 | 1 (< 1%) | 0 (0%) |
 2 | 8 (6%) | 6 (4%) |
 3 | 28 (19%) | 14 (9%) |
 4 | 69 (48%) | 25 (15%) |
 5 | 33 (23%) | 20 (12%) |
 Unknown | 6 (4%) | 67 (41%) |
 No Chemotherapy | 0 (0%) | 31 (19%) |
Margin Involvement | ||
 Positive | 63 (43%) | 39 (24%) |
 Negative | 79 (55%) | 124 (76%) |
 Unknown | 3 (2%) | 0 (0%) |
Neo-adjuvant chemotherapy | ||
 Yes | 145 (100%) | 85 (52%) |
 No | 0 (0%) | 66 (41%) |
 Missing | 0 (0%) | 12 (7%) |